Analysis of influenza A/H3N2 neuraminidase genes obtained from influenza patients in the 2011/12 and 2012/13 seasons in Japan

Hideyuki Ikematsu, Yong Chong, Kenjiro Shirane, Hidehiro Toh, Hiroyuki Sasaki, Yui Koga, Michiyo Urata, Taeko Hotta, Takeshi Uchiumi, Donchon Kang

研究成果: ジャーナルへの寄稿記事

抄録

BACKGROUND: Influenza virus has neuraminidase (NA), a surface protein with enzymatic activity that is essential for virus replication. Mutation may affect the effectiveness of NA inhibitors that are used for the treatment of influenza patients. In this study, we determined the NA gene sequences from the clinical isolates of influenza patients to examine the chronological genetic changes and the relation to drug susceptibility.

METHODS: For 96 A/H3N2 virus isolates the 50% inhibitory concentration (IC50) (48 each from the 2011-12 and 12-13 influenza seasons) was measured. RT-PCR was done with extracted viral RNA, followed by nucleotide sequencing.

RESULTS: One putative amino acid mutation, D151N, was found in an NA activity-related cite in five of ninety-six tested isolate. The mutation did not affect the IC50 value. The mutations identified at amino acid positions 387 and 400 were statistically correlated with an increased IC50 value, although the change was less than ten times, suggesting no significant difference in the clinical effectiveness. A small number .of isolates showed mutation in the T and/or B cell epitope region of NA.

CONCLUSION: No mutation that affected the IC50 value or effectiveness of NAIs was detected. Antigenic mutations of NA, which influence the selection of epidemic strains, were not determined. Continuous observation will be necessary to further clarify the genetic features of NA.

元の言語英語
ページ(範囲)16-22
ページ数7
ジャーナルFukuoka igaku zasshi = Hukuoka acta medica
106
発行部数1
出版物ステータス出版済み - 1 1 2015

Fingerprint

Neuraminidase
Human Influenza
Japan
Inhibitory Concentration 50
Mutation
Genes
H3N2 Subtype Influenza A Virus
B-Lymphocyte Epitopes
Amino Acids
T-Lymphocyte Epitopes
Viral RNA
Virus Replication
influenza A virus NA protein
Orthomyxoviridae
Membrane Proteins
Nucleotides
Observation
Polymerase Chain Reaction
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Medicine(all)

これを引用

Analysis of influenza A/H3N2 neuraminidase genes obtained from influenza patients in the 2011/12 and 2012/13 seasons in Japan. / Ikematsu, Hideyuki; Chong, Yong; Shirane, Kenjiro; Toh, Hidehiro; Sasaki, Hiroyuki; Koga, Yui; Urata, Michiyo; Hotta, Taeko; Uchiumi, Takeshi; Kang, Donchon.

:: Fukuoka igaku zasshi = Hukuoka acta medica, 巻 106, 番号 1, 01.01.2015, p. 16-22.

研究成果: ジャーナルへの寄稿記事

Ikematsu, Hideyuki ; Chong, Yong ; Shirane, Kenjiro ; Toh, Hidehiro ; Sasaki, Hiroyuki ; Koga, Yui ; Urata, Michiyo ; Hotta, Taeko ; Uchiumi, Takeshi ; Kang, Donchon. / Analysis of influenza A/H3N2 neuraminidase genes obtained from influenza patients in the 2011/12 and 2012/13 seasons in Japan. :: Fukuoka igaku zasshi = Hukuoka acta medica. 2015 ; 巻 106, 番号 1. pp. 16-22.
@article{9059bd9b370044859bf86757f8461905,
title = "Analysis of influenza A/H3N2 neuraminidase genes obtained from influenza patients in the 2011/12 and 2012/13 seasons in Japan",
abstract = "BACKGROUND: Influenza virus has neuraminidase (NA), a surface protein with enzymatic activity that is essential for virus replication. Mutation may affect the effectiveness of NA inhibitors that are used for the treatment of influenza patients. In this study, we determined the NA gene sequences from the clinical isolates of influenza patients to examine the chronological genetic changes and the relation to drug susceptibility.METHODS: For 96 A/H3N2 virus isolates the 50{\%} inhibitory concentration (IC50) (48 each from the 2011-12 and 12-13 influenza seasons) was measured. RT-PCR was done with extracted viral RNA, followed by nucleotide sequencing.RESULTS: One putative amino acid mutation, D151N, was found in an NA activity-related cite in five of ninety-six tested isolate. The mutation did not affect the IC50 value. The mutations identified at amino acid positions 387 and 400 were statistically correlated with an increased IC50 value, although the change was less than ten times, suggesting no significant difference in the clinical effectiveness. A small number .of isolates showed mutation in the T and/or B cell epitope region of NA.CONCLUSION: No mutation that affected the IC50 value or effectiveness of NAIs was detected. Antigenic mutations of NA, which influence the selection of epidemic strains, were not determined. Continuous observation will be necessary to further clarify the genetic features of NA.",
author = "Hideyuki Ikematsu and Yong Chong and Kenjiro Shirane and Hidehiro Toh and Hiroyuki Sasaki and Yui Koga and Michiyo Urata and Taeko Hotta and Takeshi Uchiumi and Donchon Kang",
year = "2015",
month = "1",
day = "1",
language = "English",
volume = "106",
pages = "16--22",
journal = "Fukuoka Acta Medica",
issn = "0016-254X",
publisher = "福岡医学会",
number = "1",

}

TY - JOUR

T1 - Analysis of influenza A/H3N2 neuraminidase genes obtained from influenza patients in the 2011/12 and 2012/13 seasons in Japan

AU - Ikematsu, Hideyuki

AU - Chong, Yong

AU - Shirane, Kenjiro

AU - Toh, Hidehiro

AU - Sasaki, Hiroyuki

AU - Koga, Yui

AU - Urata, Michiyo

AU - Hotta, Taeko

AU - Uchiumi, Takeshi

AU - Kang, Donchon

PY - 2015/1/1

Y1 - 2015/1/1

N2 - BACKGROUND: Influenza virus has neuraminidase (NA), a surface protein with enzymatic activity that is essential for virus replication. Mutation may affect the effectiveness of NA inhibitors that are used for the treatment of influenza patients. In this study, we determined the NA gene sequences from the clinical isolates of influenza patients to examine the chronological genetic changes and the relation to drug susceptibility.METHODS: For 96 A/H3N2 virus isolates the 50% inhibitory concentration (IC50) (48 each from the 2011-12 and 12-13 influenza seasons) was measured. RT-PCR was done with extracted viral RNA, followed by nucleotide sequencing.RESULTS: One putative amino acid mutation, D151N, was found in an NA activity-related cite in five of ninety-six tested isolate. The mutation did not affect the IC50 value. The mutations identified at amino acid positions 387 and 400 were statistically correlated with an increased IC50 value, although the change was less than ten times, suggesting no significant difference in the clinical effectiveness. A small number .of isolates showed mutation in the T and/or B cell epitope region of NA.CONCLUSION: No mutation that affected the IC50 value or effectiveness of NAIs was detected. Antigenic mutations of NA, which influence the selection of epidemic strains, were not determined. Continuous observation will be necessary to further clarify the genetic features of NA.

AB - BACKGROUND: Influenza virus has neuraminidase (NA), a surface protein with enzymatic activity that is essential for virus replication. Mutation may affect the effectiveness of NA inhibitors that are used for the treatment of influenza patients. In this study, we determined the NA gene sequences from the clinical isolates of influenza patients to examine the chronological genetic changes and the relation to drug susceptibility.METHODS: For 96 A/H3N2 virus isolates the 50% inhibitory concentration (IC50) (48 each from the 2011-12 and 12-13 influenza seasons) was measured. RT-PCR was done with extracted viral RNA, followed by nucleotide sequencing.RESULTS: One putative amino acid mutation, D151N, was found in an NA activity-related cite in five of ninety-six tested isolate. The mutation did not affect the IC50 value. The mutations identified at amino acid positions 387 and 400 were statistically correlated with an increased IC50 value, although the change was less than ten times, suggesting no significant difference in the clinical effectiveness. A small number .of isolates showed mutation in the T and/or B cell epitope region of NA.CONCLUSION: No mutation that affected the IC50 value or effectiveness of NAIs was detected. Antigenic mutations of NA, which influence the selection of epidemic strains, were not determined. Continuous observation will be necessary to further clarify the genetic features of NA.

UR - http://www.scopus.com/inward/record.url?scp=84930320576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930320576&partnerID=8YFLogxK

M3 - Article

C2 - 25942938

AN - SCOPUS:84930320576

VL - 106

SP - 16

EP - 22

JO - Fukuoka Acta Medica

JF - Fukuoka Acta Medica

SN - 0016-254X

IS - 1

ER -